Commitments and Contingencies (Details) - USD ($)			1 Months Ended	3 Months Ended
	Mar. 18, 2024	Oct. 18, 2023	Nov. 29, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Commitments and Contingencies [Line Items]
Reimbursement of legal costs					$ 1,250,000
Several liability		$ 14,684,833
Net sales of epoladerm		5.00%
Net sales of envelta		7.50%
Potential damages		$ 13,400,000
Trade amount			$ 6,700,000
Proffered documents (in Shares)			1,182
Several liability			$ 28,382
Litigation settlement	$ 2,500,000
Royalties annual net sales percentage				6.00%
Initial payment				$ 3,500,000
Accrued litigation				2,500,000		$ 6,000,000
Accrual litigation				2,500,000
Misuse of Scilex [Member]
Commitments and Contingencies [Line Items]
Potential damages		$ 1,300,000
Minimum [Member]
Commitments and Contingencies [Line Items]
Net sales of probudur		8.00%
Development of epoladerm			18 months
Royalty rate			1.00%
Litigation settlement				3,500,000
Maximum [Member]
Commitments and Contingencies [Line Items]
Net sales of probudur		11.00%
Development of epoladerm			27 days
Royalty rate			3.00%
Litigation settlement				6,000,000
Mr Mack and Virpax [Member]
Commitments and Contingencies [Line Items]
Potential damages		$ 6,700,000
Accrued litigation				711,000		$ 711,000
Litigation [Member]
Commitments and Contingencies [Line Items]
Initial payment				$ 3,500,000